Lena Jendeberg

Direttore/Membro del Consiglio presso ATTANA AB

60 anni

Health Technology

Health Services

Consumer Services

Profilo

Lena Jendeberg is currently working as a Director at Attana AB since 2018.
Prior to this, she worked as a Vice President-Development at Modus Therapeutics AB.
Dr. Jendeberg holds a doctorate degree from the Royal Institute of Technology.

Posizioni attive di Lena Jendeberg

Società	Posizione	Inizio
ATTANA AB	Direttore/Membro del Consiglio	01/01/2018

Tutte le posizioni attive di Lena Jendeberg

Precedenti posizioni note di Lena Jendeberg

Società	Posizione	Fine
Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Lena Jendeberg

Formazione di Lena Jendeberg

Royal Institute of Technology

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Lena Jendeberg

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ATTANA AB	Health Services

Aziende private	1
Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	Health Technology